Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Prophylactic HIV Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Prophylactic HIV Drugmarket, defines the market attractiveness level of Prophylactic HIV Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Prophylactic HIV Drug industry, describes the types of Prophylactic HIV Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Prophylactic HIV Drug market and the development prospects and opportunities of Prophylactic HIV Drug industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Prophylactic HIV Drug market in Chapter 13.
By Player:
Bristol-Myers Squibb
Gilead Sciences
Roche
Merck
Cipla
Mylan
By Type:
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Integrase Inhibitor
By End-User:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Prophylactic HIV Drug Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Prophylactic HIV Drug Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Prophylactic HIV Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Prophylactic HIV Drug Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Prophylactic HIV Drug Market Analysis and Outlook to 2022
-
7.1 Global Prophylactic HIV Drug Consumption (2017-2022)
-
7.2 United States Prophylactic HIV Drug Consumption (2017-2022)
-
7.3 Europe Prophylactic HIV Drug Consumption (2017-2022)
-
7.4 China Prophylactic HIV Drug Consumption (2017-2022)
-
7.5 Japan Prophylactic HIV Drug Consumption (2017-2022)
-
7.6 India Prophylactic HIV Drug Consumption (2017-2022)
-
7.7 South Korea Prophylactic HIV Drug Consumption (2017-2022)
8 Region and Country-wise Prophylactic HIV Drug Market Analysis and Outlook to 2028
-
8.1 Global Prophylactic HIV Drug Consumption Forecast (2022-2028)
-
8.2 United States Prophylactic HIV Drug Consumption Forecast (2022-2028)
-
8.3 Europe Prophylactic HIV Drug Consumption Forecast (2022-2028)
-
8.4 China Prophylactic HIV Drug Consumption Forecast (2022-2028)
-
8.5 Japan Prophylactic HIV Drug Consumption Forecast (2022-2028)
-
8.6 India Prophylactic HIV Drug Consumption Forecast (2022-2028)
-
8.7 South Korea Prophylactic HIV Drug Consumption Forecast (2022-2028)
9 Global Prophylactic HIV Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Prophylactic HIV Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Integrase Inhibitor Consumption and Growth Rate (2017-2022)
-
9.2 Global Prophylactic HIV Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacy Consumption and Growth Rate (2017-2022)
10 Global Prophylactic HIV Drug Market Outlook by Types and Applications to 2028
-
10.1 Global Prophylactic HIV Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Integrase Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Prophylactic HIV Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)
11 Global Prophylactic HIV Drug Import and Export Analysis (Top 5 Countries)
-
11.1 Global Prophylactic HIV Drug Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Prophylactic HIV Drug Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Prophylactic HIV Drug Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Prophylactic HIV Drug Market Competitive Analysis
-
14.1 Bristol-Myers Squibb
-
14.1.1 Bristol-Myers Squibb Company Details
-
14.1.2 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Bristol-Myers Squibb Prophylactic HIV Drug Product and Service
-
14.2 Gilead Sciences
-
14.2.1 Gilead Sciences Company Details
-
14.2.2 Gilead Sciences Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Gilead Sciences Prophylactic HIV Drug Product and Service
-
14.3 Roche
-
14.3.1 Roche Company Details
-
14.3.2 Roche Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Roche Prophylactic HIV Drug Product and Service
-
14.4 Merck
-
14.4.1 Merck Company Details
-
14.4.2 Merck Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Merck Prophylactic HIV Drug Product and Service
-
14.5 Cipla
-
14.5.1 Cipla Company Details
-
14.5.2 Cipla Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Cipla Prophylactic HIV Drug Product and Service
-
14.6 Mylan
-
14.6.1 Mylan Company Details
-
14.6.2 Mylan Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Mylan Prophylactic HIV Drug Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Prophylactic HIV Drug
-
Figure Prophylactic HIV Drug Picture
-
Table Global Prophylactic HIV Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Prophylactic HIV Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Prophylactic HIV Drug Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Prophylactic HIV Drug Consumption by Country (2017-2022)
-
Figure United States Prophylactic HIV Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Prophylactic HIV Drug Consumption and Growth Rate (2017-2022)
-
Figure China Prophylactic HIV Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Prophylactic HIV Drug Consumption and Growth Rate (2017-2022)
-
Figure India Prophylactic HIV Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Prophylactic HIV Drug Consumption and Growth Rate (2017-2022)
-
Figure Global Prophylactic HIV Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Prophylactic HIV Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Prophylactic HIV Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Prophylactic HIV Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Prophylactic HIV Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Prophylactic HIV Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Prophylactic HIV Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Consumption and Growth Rate (2017-2022)
-
Figure Global Integrase Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Integrase Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Prophylactic HIV Drug Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Prophylactic HIV Drug Export by Region (Top 5 Countries) (2017-2028)
-
Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Prophylactic HIV Drug Product and Service
-
Table Gilead Sciences (Foundation Year, Company Profile and etc.)
-
Table Gilead Sciences Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Sciences Prophylactic HIV Drug Product and Service
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Prophylactic HIV Drug Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Prophylactic HIV Drug Product and Service
-
Table Cipla (Foundation Year, Company Profile and etc.)
-
Table Cipla Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Prophylactic HIV Drug Product and Service
-
Table Mylan (Foundation Year, Company Profile and etc.)
-
Table Mylan Prophylactic HIV Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mylan Prophylactic HIV Drug Product and Service
-
